Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Solomon, B. [1 ]
Bang, Y. J. [2 ]
Camidge, D. R. [3 ]
Iafrate, A. J. [4 ]
Kwak, E. L.
Maki, R. G. [5 ]
Ou, S. I. [6 ]
Salgia, R. [7 ]
Shaw, A.
Clark, J.
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Australia
[2] Seoul Natl Univ, Dept Internal Med, Seoul, South Korea
[3] Univ Colorado, Ctr Canc, Div Med Oncol, Aurora, CO USA
[4] Massachusetts Gen Hosp, Translat Res Lab, Boston, MA 02114 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[6] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA
[7] Univ Chicago, Ctr Canc, Hematol Oncol Sect, Chicago, IL 60637 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72076-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 117
页数：1
相关论文
共 50 条
  • [41] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    [J]. VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [42] A BUDGET IMPACT ANALYSIS TO ESTIMATE THE COST SAVINGS FROM ALECTINIB ON PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CRIZOTINIB
    Orfanos, P.
    Becker, U.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A719 - A719
  • [43] Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer in Canada
    Hurry, Manjusha
    Zhou, Zheng-Yi
    Zhang, Jie
    Zhang, Chenxue
    Fan, Liangyi
    Rebeira, Mayvis
    Xie, Jipan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 936 - 944
  • [44] Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
    Ou, Sai-Hong Ignatius
    Kwak, Eunice L.
    Siwak-Tapp, Christina
    Dy, Joni
    Bergethon, Kristin
    Clark, Jeffrey W.
    Camidge, D. Ross
    Solomon, Benjamin J.
    Maki, Robert G.
    Bang, Yung-Jue
    Kim, Dong-Wan
    Christensen, James
    Tan, Weiwei
    Wilner, Keith D.
    Salgia, Ravi
    Iafrate, A. John
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (05) : 942 - 946
  • [45] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [46] Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer
    Ou, Sai-Hong Ignatius
    Bazhenova, Lyudmila
    Camidge, D. Ross
    Solomon, Benjamin J.
    Herman, June
    Kain, Tatiana
    Bang, Yung-Jue
    Kwak, Eunice L.
    Shaw, Alice T.
    Salgia, Ravi
    Maki, Robert G.
    Clark, Jeffrey W.
    Wilner, Keith D.
    Iafrate, A. John
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 2044 - 2046
  • [47] Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion
    Pan, Yingying
    Xiao, Wenjing
    Ye, Feng
    Wang, Huijuan
    Shen, Yihong
    Yu, Xinmin
    Han, Xiao
    Chu, Qian
    Zhou, Caicun
    Zhang, Zhihong
    Ren, Shengxiang
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (12)
  • [48] CT image characteristics of anaplastic lymphoma kinase fusion gene positive (ALK-P) advanced stage non-small cell lung cancer (NSCLC).
    Oyakawa, Takuya
    Takahashi, Toshiaki
    Imai, Hisao
    Akamatsu, Hiroaki
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Yamamoto, Nobuyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] BUDGET IMPACT OF ALECTINIB IN THE TREATMENT OF NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
    Kourkoulas, N.
    Kyriopoulos, D.
    Athanasakis, K.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A424 - A424
  • [50] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
12345